Sponsor

Criterium, Inc.

Clinical research sponsor

Published trials9

Recruiting shown0

Roles2

SourceClinicalTrials.gov

Clinical trials

9 shown

Tucatinib+Trastuzumab+Eribulin in HER2+ MBCNCT05458674 · lead sponsor · 2024-01-30

ACTIVE_NOT_RECRUITING

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.NCT05230810 · lead sponsor · 2022-08-25

ACTIVE_NOT_RECRUITING

A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain MetastasisNCT05180422 · lead sponsor · 2022-06-15

WITHDRAWN

CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLCNCT04739358 · lead sponsor · 2022-05-25

TERMINATED

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast CancerNCT04791384 · lead sponsor · 2022-04-21

TERMINATED

DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)NCT04567420 · lead sponsor · 2021-02-09

ACTIVE_NOT_RECRUITING

Trial of Brigatinib After Treatment With Next-Generation ALK InhibitorsNCT02706626 · lead sponsor · 2017-03-09

TERMINATED

Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other DiseasesNCT03389399 · collaborator · 2018-02-22

COMPLETED

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast CancerNCT03054363 · collaborator · 2017-11-27

COMPLETED

Sponsor roles

lead sponsor7

collaborator2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.